Update
$AIM ImmunoTech(AIM.US$ AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions 12 MINUTES AGO, 12:00 PM EST VIA GLOBENEWSWIRE AIM SHARE No severe adverse events reported to date Topline data expected as early as Q1 2024![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
